Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

Australia's CSL, which earlier this year paused plans to put its CSL Seqirus vaccine division up for sale, has opened the doors to a new $1 billion cell-based influenza vaccine and antivenom ...

CSL Ltd's share price has underperformed in the S&P/ASX 200 Index, dropping by approximately 30% over the past 12 months. Analysts see potential in CSL, with an average price target indicating a 33% ...

CSL has said that with flu jab rates in the US down between 12% and 14% this year, it has decided to delay the planned spinout of its Seqirus vaccines business and cut its profit forecast for the ...

ASX Ltd drops almost 7% as it implements strategic commitments in response to ASIC's inquiries, requiring significant capital accumulation, which places investor focus on regulatory compliance and ...

Asia-Pacific's penicillin G acylase market surges on China's Shandong mega-scale (60% global 6-APA) and India's PLI ramps ...

BMW's M division has a new halo car, and it also revives a legendary nameplate. The original BMW 3.0 CSL was a homologation special from the early 1970s, and the 'L' in its name came to signify ...

CSL Ltd (ASX: CSL) shares are having a poor start to the week. In afternoon trade, the biotechnology giant's shares are down 1.5% to $180.99. There are a couple of reasons why investors have been ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Investopedia contributors come from a range of backgrounds, and over 25 years there have been thousands of expert writers and editors who have contributed. Mortgage-backed securities (MBS) and ...

Process chemistry involves the development and optimization of production processes for chemical compounds, and the scaling up of laboratory reactions, particularly in the pharmaceutical sector. The ...